US Archives - Page 52 of 112 - European Medical Journal

Comparing Immunosuppressants: What Works Best in Systemic Sclerosis?

A recent analysis from the RESOLVE-1 trial has highlighted the potential of mycophenolate mofetil (MMF) in treating diffuse cutaneous systemic sclerosis (dcSSc), particularly in early-stage disease.

Remdesivir and COVID-19: Are Treatment Guidelines Keeping Up?

A new systematic review and meta-analysis of over 1.3 million patients has confirmed that remdesivir significantly improves survival rates for hospitalized COVID-19 patients, yet treatment guidelines may not fully reflect this evolving evidence.

Why Diversity in Clinical Trials Matters More Than Ever

Increasing diversity in research, from basic science to clinical trials, remains essential for advancing equitable healthcare outcomes.

Stroke's Financial Toll on Families: New Insights

Financial challenges faced by family surrogate decision-makers of stroke patients were highlighted in a new study that revealed that nearly half experience moderate to severe concerns about affording stroke-related medical expenses.

Continuous Immunotherapy's Impact on Advanced Lung Cancer

In a pivotal development for the oncology community, a recent retrospective study has demonstrated that continuing immunotherapy beyond disease progression offers significant survival benefits for patients with advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

New Discovery Reshapes Alveolar Formation Understanding

For decades, researchers believed that alveoli, the tiny air sacs responsible for gas exchange, formed by airspace subdivision via ingrowing septa.

Are Dermatology Residents Truly Prepared for Skin of Color Cases?

Achieving comprehensive education in skin of colour (SoC) dermatology remains a challenge in residency programs, with significant disparities in exposure to diverse skin tones across institutions.

Alopecia Treatment Shows Hair Regrowth After Stopping

Patients with severe alopecia areata (AA) may experience prolonged hair regrowth even after discontinuing treatment with bempikibart, according to findings from the SIGNAL-AA phase 2a study presented at the American Academy of Dermatology (AAD) Annual Meeting.

CMV Linked to Infant and Child Mortality in Low-Income Nations

Cytomegalovirus (CMV) plays a significant role in stillbirths and childhood deaths in low- and middle-income countries (LMICs), according to the results of a new study.

New Oral TYK2 Inhibitor Shows Psoriasis Efficacy

A phase 2 clinical trial has demonstrated that a once-daily oral tyrosine kinase 2 (TYK2) inhibitor significantly improves symptoms in adults with moderate to severe plaque psoriasis, achieving high clearance rates with a safety profile comparable to placebo.